Skip to content
value.today

Selexys Pharmaceuticals Corp.

Total raised
$43 M
1 round on record
Latest round
$43 M
Sep 2012
First round on record
Sep 2012
Today
Private
No later event on record

Funding rounds

1 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Selexys Pharmaceuticals Corp.
MonthRaisedRaiseSizeInvestorsSoldFiling
Sep 2012$43 MNo. 1$10 to $50 million

Selexys Pharmaceuticals Corp.: Raise no. 1, Sep 2012

Investors in this round

57 investors had bought by the notice of Feb 23, 2015: 57 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$43 M of $43 M offered
Smallest investment taken
$13,217
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
No revenue
Sales commissions
none
Finders' fees
none
Paid to its own people
$4,864,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • David Falconer · Executive Officer
  • Richard Alvarez · Executive Officer
  • Russell Rother · Executive Officer
  • Scott Rollins, Ph.D. · Executive Officer, Director
  • David Keiser · Director
  • Philip Jones, M.D. · Director
  • Rodger McEver, M.D. · Director
  • Todd Foley · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Includes warrant issued for $10,000,000, $24,459,532 of Series A Preferred Shares at the initial closing ($10,659,534 of which was from the conversion of outstanding notes), and $8,737,299 of Series A Preferred Shares at the second closing.”
  • On the use of proceeds: “Estimated amount includes officers' salaries and bonuses paid since the initial filing and estimated salaries and potential bonuses for the period over which the proceeds of the offering are expected to be expended.”

Signed by Douglas A. Branch, Secretary. Source: SEC Form D and 1 amendment, newest notice filed Feb 23, 2015. Read the notice at the SEC.

equity, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Selexys Pharmaceuticals Corp. had no revenue when it filed its newest notice of a funding round (Feb 2015).

    SEC Form D (revenue range) · Feb 2015

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Feb 2015

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Selexys Pharmaceuticals Corp. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 57 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Selexys Pharmaceuticals Corp.
NameRoleNamed in
David FalconerExecutive officerFeb 2015
Richard AlvarezExecutive officerFeb 2015
Russell RotherExecutive officerFeb 2015
Scott Rollins, Ph.D.Executive officerFeb 2015
David KeiserDirectorFeb 2015
Philip Jones, M.D.DirectorFeb 2015
Rodger McEver, M.D.DirectorFeb 2015
Scott Rollins, Ph.D.DirectorFeb 2015
Todd FoleyDirectorFeb 2015